Here are two more encouraging excerpts from the same conference call ...
1. "Based on the pace of discussions and level of interest I can say we are optimistic we will be able to generate one or more partnerships in the first half of . We are fortunate to have multiple un-partnered programs, a strong discovery engine and a good cash position, all of which gives us flexibility and we intent to use that flexibility as an advantage to get the best choices on the table."
2. "Brian Martin - Barclays Capital
But 9090 clearly you all have shown pre-clinical data that's shown to be superior during the first generation 17 AAG and analogues. But how do you see yourselves positioned versus other earlier stage synthetic compounds like in Pfizer Serenex 5422 or the Astex compound or the Novartis compounds.
Vojo Vukovic (SNTA)
I think that's a great question. Let me begin by answering the question that we have synthesized in our labs really all of the claimed Hsp90 inhibitors that we are aware of for which the structures under public premise, we're able to do extensive testing in our labs and by our experiments as well as the experienced results from our collaborators we see that 9090 is FAR SUPERIOR (my caps) to 17-AG family of inhibitors that a number of companies are developing."